Lurbinectedin is not recommended for all cancers. It has been approved by the FDA for the treatment of metastatic small cell lung cancer (SCLC) in patients who have previously received chemotherapy [2]. Lurbinectedin is a novel anticancer agent that targets transcription factors and inhibits DNA repair pathways [3]. It has shown promising results in clinical trials for the treatment of various types of cancers, including ovarian cancer, endometrial cancer, and breast cancer [3]. However, further research is needed to determine its efficacy and safety in these cancers [3]. Additionally, Lurbinectedin is still under investigation for the treatment of other types of cancer, and its efficacy in these cancers is yet to be established [1].

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-lurbinectedin-metastatic-small-cell-lung-cancer
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165873/